Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 2 of 5804
-
Can a Pre-Surgery drug combo wipe out early lung cancer?
⭐️ CURE ⭐️ Not yet recruitingThe study will investigate the role of cemiplimab in combination with platinum doublet chemotherapy in stage I resectable non-small cell lung cancer (NSCLC). Sub-4cm NSCLC tumors are highly lethal malignancies, yet no therapies are used in these patients to improve chances of sur…
Phase: PHASE2 • Sponsor: Medical University of South Carolina • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
Brain implant aims to give voice to those trapped in silence
Disease control Not yet recruitingEighteen million people worldwide are affected by speech disorders. Locked-in syndrome (LIS) represents the most extreme form of communication disability resulting from motor impairment. In France, the Association du Locked-In Syndrome (ALIS) reports approximately 500 individuals…
Phase: NA • Sponsor: University Hospital, Grenoble • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat lupus
Disease control Not yet recruitingSystemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the immune system mistakenly attacks the body's own tissues and organs. The disease can affect the skin, joints, kidneys, blood cells, brain, and other organs, leading to significant health problems and r…
Phase: PHASE1, PHASE2 • Sponsor: University of Sao Paulo • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Could MDMA help heal PTSD in soldiers? new trial investigates
Disease control Not yet recruitingThis study is a Phase 2, randomized, double-blind, active-controlled, two-arm, single-site clinical trial designed to evaluate the safety, tolerability, and feasibility of MDMA-Assisted Therapy (MDMA-AT) for Service Members (Active Duty, Guard, or Reserve) diagnosed with moderate…
Phase: PHASE2 • Sponsor: U.S. Army Medical Research and Development Command • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug duo aims to outsmart EGFR-mutant lung cancer
Disease control Not yet recruitingThe purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherap…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Can a fourth drug tip the scales against an aggressive leukemia?
⭐️ CURE ⭐️ Not yet recruitingAcute myeloid leukemia (AML) with FLT3 mutation accounts for 30% of patients and is associated with a poor prognosis. Because of the FLT3 mutation, a tyrosine kinase inhibitor, midostaurin (MIDO), is added to the standard treatment with daunorubicin and cytarabine, from D8 to D21…
Phase: PHASE1, PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: ⭐️ CURE ⭐️
Last updated Jul 26, 2026 00:00 UTC
-
New drug targets Hard-to-Treat pancreatic cancer by hitting a common mutation
Disease control Not yet recruitingThis study plans to enroll participants with previously treated advanced pancreatic cancer and harbor centrally confirmed KRAS G12D mutation. Eligible participants will be randomized 1:1 to DN022150 Monotherapy or Investigator's Choice Chemotherapy
Phase: PHASE3 • Sponsor: Jiangxi Kvvit Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Gene therapy aims to tame rare immune disorder
Disease control Not yet recruitingThe purpose of this study is to evaluate the safety and efficacy of FOXP3-T4 (an autologous gene therapy) alone or in combination with low-dose IL-2 for the treatment of IPEX syndrome. The therapy involves the transplantation of autologous CD4+ T-cells transduced ex vivo with the…
Phase: PHASE1, PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Gene therapy aims to cure Transfusion-Dependent thalassemia in a single shot
⭐️ CURE ⭐️ Not yet recruitingThalassemia is a group of recessively inherited hemoglobin disorders characterized by reduced or no production of hemoglobin and chronic anemia of varying severity. Severe β-thalassemia is transfusion-dependent thalassemia (TDT) and requires life-long transfusion, iron overload i…
Phase: PHASE2 • Sponsor: Prince of Wales Hospital, Shatin, Hong Kong • Aim: ⭐️ CURE ⭐️
Last updated Jul 25, 2026 00:00 UTC
-
Ebola breakthrough? new trial aims to stop virus after exposure
Prevention Not yet recruitingEBO-PEP is a multicentre, multi-epidemic, phase III, comparative, controlled, randomised, strict superiority trial in two unblinded parallel arms. The trial will be open during EVD epidemics and will recruit asymptomatic participants at high risk of developing EVD. Participants…
Phase: PHASE3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Prevention
Last updated Jun 27, 2026 08:12 UTC
-
Ultra-Fast CAR-T cells aim to beat back tough lymphomas
⭐️ CURE ⭐️ Not yet recruitingThe goal of this Phase II single-arm, open-label clinical trial is to evaluate whether UF-KURE19, an autologous CD19-directed CAR-T cell therapy manufactured t…The goal of this Phase II single-arm, open-label clinical trial is to evaluate whether UF-KURE19, an autologous CD19-dir…
Phase: PHASE2 • Sponsor: Kure Cells, INC • Aim: ⭐️ CURE ⭐️
Last updated Jul 22, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat scleroderma in landmark trial
Disease control Recruiting nowThe purpose of this study is to compare the efficacy and safety of BMS-986353 versus standard of care in participants with active Systemic Sclerosis
Phase: PHASE3 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a spinal injection restore movement after paralysis?
⭐️ CURE ⭐️ Not yet recruitingThis is a Phase 3, multicenter, open-label, single-arm additional study to evaluate the efficacy of intrathecal KP-100IT in patients with acute spinal cord injury. Eligible patients will receive KP-100 0.6 mg/body by intrathecal administration once per week for a total of 5 doses…
Phase: PHASE3 • Sponsor: Kringle Pharma, Inc. • Aim: ⭐️ CURE ⭐️
Last updated Jul 25, 2026 00:00 UTC
-
Scientists test CAR-T cells made inside the body to fight Hard-to-Treat myeloma
⭐️ CURE ⭐️ Recruiting nowThis study is an investigator-initiated, single-center, single-arm clinical study with a target population of patients with relapsed or refractory multiple myeloma. It is an early exploratory clinical study evaluating the safety, tolerability, and preliminary efficacy of PICX In…
Phase: PHASE1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: ⭐️ CURE ⭐️
Last updated Jul 22, 2026 00:00 UTC
-
Could a Liver-Stage malaria vaccine shield mothers and babies?
⭐️ VACCINE ⭐️ Recruiting nowA randomized double blind, placebo-controlled study to assess the safety, tolerability, immunogenicity, and protective efficacy of 1, 6, 29-day PfSPZ-LARC2 Vaccine regimen given at a dose of 2 x10\^5 PfSPZ or placebo in healthy WOCBP, who are on pregnancy prevention during vaccin…
Phase: PHASE2 • Sponsor: Sanaria Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 25, 2026 00:00 UTC
-
Can a single infusion of engineered immune cells beat back hard-to-treat multiple myeloma?
⭐️ CURE ⭐️ Not yet recruitingA single-arm, open-label, multicenter, dose-escalation clinical trial to evaluate the safety, tolerability, and preliminary efficacy of KIV-318 Injection in patients with relapsed/refractory multiple myeloma.
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: ⭐️ CURE ⭐️
Last updated Jul 26, 2026 00:00 UTC
-
Thinking your way to movement: brain-computer interface tested for hand function in tetraplegia
Disease control Recruiting nowThis prospective, multicenter, single-arm clinical trial will enroll subjects with tetraplegia secondary to spinal cord injury. An implantable brain-computer interface system for compensatory hand motor function will be used to reconstruct upper-limb function, so as to evaluate t…
Phase: NA • Sponsor: NeuroXess Technology (shanghai) Co.,Ltd. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Twice-Yearly HIV shot could replace daily pill regimen
Disease control Not yet recruitingThe goal of this clinical study is to compare how effective a long-acting treatment of injectable combination of lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) is versus continuing a daily oral HIV treatment in adults with HIV-1 whose virus is already well controlled…
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Gene therapy aims to free Beta-Thalassemia patients from lifelong transfusions
Disease control Not yet recruitingThis is a prospective, dual-centre, single dose, Phase IIb, single arm, open label study. The proposed clinical trial involves a single infusion of autologous HSPCs genetically modified with the GLOBE lentiviral vector, using an improved transduction protocol in 9 patients affect…
Phase: PHASE2 • Sponsor: Fondazione Telethon • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Engineered immune cells target deadly brain tumors in children
Disease control Not yet recruitingThis study will evaluate BCB-276, an investigational B7-H3-targeted Chimeric Antigen Receptor (CAR) T cell therapy, in children and young adults with diffuse intrinsic pontine glioma (DIPG). DIPG is a rare and aggressive brain tumor with limited treatment options. CAR T cell ther…
Phase: PHASE2 • Sponsor: BrainChild Bio, Inc • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC